Computational Methods in Partial Differential Equations ['Introductory Mathematics for Scientists & Engineers' Series]

Mitchell, A.R.

ISBN 10: 0471610917 / ISBN 13: 9780471610915

Published by John Wiley & Sons Ltd., London, 1969

About this Item

Mathematical/scientific exposition. First Edn., 1969; xiii+[i]+255pp.illus. bw. diagrams. Faintly tanned spine slightly rubbed at top/tail/edges, but complete/intact; rear cover lightly creased at top corner; covers slightly rubbed at corners, but clean/very bright; page edges lightly tanned, but text fresh, pages clean/bright/quite crisp. Binding firm, all complete/intact. Name in ink to verso front cover, but no annotations/highlighting to text. G+ PRICE INCLUDES UK POSTAGE & PACKING.

Seller Inventory # 26839

Bibliographic Details

• Title: Computational Methods in Partial Differential Equations ['Introductory Mathematics for Scientists & Engineers' Series]
• Publisher: John Wiley & Sons Ltd., London
• Publication Date: 1969
• ISBN 10: 0471610917
• ISBN 13: 9780471610915
• Binding: Soft Cover
• Edition: First Edition.
• Condition: Good Plus
• Dust Jacket Condition: No Jacket (as issued)
• Book Type: Paperback

About this title

Synopsis

The forces that shape America's most powerful consumer agency

Because of the importance of what it regulates, the FDA comes under tremendous political, industry, and consumer pressure. But the pressure goes far beyond the ordinary lobbying of Washington trade groups. Its mandate-one quarter of the national economy-brings the FDA into the middle of some of the most important and contentious issues of modern society. From "designer" babies and abortion to the price of prescription drugs and the role of government itself, Inside the FDA takes readers on an intriguing journey into the world of today's most powerful consumer agency.

In a time when companies continue to accuse the FDA of nitpicking and needlessly delaying needed new drugs, and consumers are convinced that the agency bends to industry pressure by rushing unsafe drugs to market, Inside the FDA digs deep to reveal the truth. Through scores of interviews and real-world stories, Hawthorne also shows how and why the agency makes some of its most controversial decisions as well as how its recent reaction to certain issues-including the revolutionary cancer drug Erbitux, stem cell research, and bioengineering of food-may jeopardize its ability to keep up with future scientific developments.

Inside the FDA takes a closer look at the practices, people, and politics of this crucial watchdog in light of the competing pressures and trends of modern society, revealing what the FDA is supposed to do, what it actually does-and fails to do-who it influences, and how it could better fulfill its mandate. The decisions that the FDA makes are literally life and death. Inside the FDA provides a sophisticated account of how this vitally important agency struggles to balance bureaucracy and politics with its overriding mission to promote the country's health.

About the Author

FRAN HAWTHORNE is Senior Contributing Editor of Institutional Investor and has connections deep within the business and finance communities. Hawthorne has been covering health care and business for more than twenty years for Fortune, Crain’s New York Business, and other publications, and she now writes regularly for such newspapers and magazines as the New York Times, Worth, and Self. She is the author of The Merck Druggernaut, which is also published by Wiley.